| abstract |
The present invention relates to use of a compound interfering with integrin β3/Src interaction. Specifically, the present invention provides use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof for preparing a composition or a formulation. The composition or the formulation is used for one or more selected from a group consisting of: (1) selectively inhibiting external inward signal transduction mediated by interaction between integrin β3 and Src kinase; (2) preventing and/or treating diseases related to the external inward signal transduction mediated by interaction between integrin β3 and Src kinase; (3) preventing and/or treating thrombi; (4) preventing and/or treating tumors; (5) preventing and/or treating osteoporosis; and (6) preventing and/or treating endothelial cell mediated vascular formation. |